These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 17311370)

  • 1. Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9.
    Locuson CW; Gannett PM; Ayscue R; Tracy TS
    J Med Chem; 2007 Mar; 50(6):1158-65. PubMed ID: 17311370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation and evaluation of a CYP2C9 heteroactivation pharmacophore.
    Egnell AC; Eriksson C; Albertson N; Houston B; Boyer S
    J Pharmacol Exp Ther; 2003 Dec; 307(3):878-87. PubMed ID: 14557374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation, characterization, and substrate metabolism of gold-immobilized cytochrome P450 2C9.
    Gannett PM; Kabulski J; Perez FA; Liu Z; Lederman D; Locuson CW; Ayscue RR; Thomsen NM; Tracy TS
    J Am Chem Soc; 2006 Jul; 128(26):8374-5. PubMed ID: 16802783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling and synthesis of novel tight-binding inhibitors of cytochrome P450 2C9.
    Peng CC; Rushmore T; Crouch GJ; Jones JP
    Bioorg Med Chem; 2008 Apr; 16(7):4064-74. PubMed ID: 18255300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Site of metabolism prediction on cytochrome P450 2C9: a knowledge-based docking approach.
    Tarcsay A; Kiss R; Keseru GM
    J Comput Aided Mol Des; 2010 May; 24(5):399-408. PubMed ID: 20361237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of metabolism by cytochrome P450 2C9: alignment and docking studies of a validated database of substrates.
    Sykes MJ; McKinnon RA; Miners JO
    J Med Chem; 2008 Feb; 51(4):780-91. PubMed ID: 18237107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development.
    Zhou SF; Zhou ZW; Yang LP; Cai JP
    Curr Med Chem; 2009; 16(27):3480-675. PubMed ID: 19515014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The molecular basis of dapsone activation of CYP2C9-catalyzed nonsteroidal anti-inflammatory drug oxidation.
    Nair PC; Burns K; Chau N; McKinnon RA; Miners JO
    J Biol Chem; 2023 Dec; 299(12):105368. PubMed ID: 37866634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effector-mediated alteration of substrate orientation in cytochrome P450 2C9.
    Hummel MA; Gannett PM; Aguilar JS; Tracy TS
    Biochemistry; 2004 Jun; 43(22):7207-14. PubMed ID: 15170358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of kinetic observations.
    Hutzler JM; Wienkers LC; Wahlstrom JL; Carlson TJ; Tracy TS
    Arch Biochem Biophys; 2003 Feb; 410(1):16-24. PubMed ID: 12559973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites.
    Ahlström MM; Ridderström M; Zamora I
    J Med Chem; 2007 Nov; 50(22):5382-91. PubMed ID: 17915853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2C9 protein interactions with cytochrome b(5): effects on the coupling of catalysis.
    Locuson CW; Wienkers LC; Jones JP; Tracy TS
    Drug Metab Dispos; 2007 Jul; 35(7):1174-81. PubMed ID: 17446262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heteroactivator effects on the coupling and spin state equilibrium of CYP2C9.
    Locuson CW; Gannett PM; Tracy TS
    Arch Biochem Biophys; 2006 May; 449(1-2):115-29. PubMed ID: 16545770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective virtual screening protocol for CYP2C9 ligands using a screening site constructed from flurbiprofen and S-warfarin pockets.
    Polgár T; Menyhárd DK; Keseru GM
    J Comput Aided Mol Des; 2007 Sep; 21(9):539-48. PubMed ID: 17960328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model.
    Hutzler JM; Hauer MJ; Tracy TS
    Drug Metab Dispos; 2001 Jul; 29(7):1029-34. PubMed ID: 11408370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: kinetics and structural requirements.
    Hutzler JM; Kolwankar D; Hummel MA; Tracy TS
    Drug Metab Dispos; 2002 Nov; 30(11):1194-200. PubMed ID: 12386124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrochemically driven drug metabolism via cytochrome P450 2C9 isozyme microsomes with cytochrome P450 reductase and indium tin oxide nanoparticle composites.
    Xu X; Wei W; Huang M; Yao L; Liu S
    Chem Commun (Camb); 2012 Aug; 48(63):7802-4. PubMed ID: 22743353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural characterization of human cytochrome P450 2C19: active site differences between P450s 2C8, 2C9, and 2C19.
    Reynald RL; Sansen S; Stout CD; Johnson EF
    J Biol Chem; 2012 Dec; 287(53):44581-91. PubMed ID: 23118231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part II.
    Mo SL; Zhou ZW; Yang LP; Wei MQ; Zhou SF
    Curr Drug Metab; 2009 Dec; 10(10):1127-50. PubMed ID: 20167000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme source effects on CYP2C9 kinetics and inhibition.
    Kumar V; Rock DA; Warren CJ; Tracy TS; Wahlstrom JL
    Drug Metab Dispos; 2006 Nov; 34(11):1903-8. PubMed ID: 16928789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.